Vertex Pharmaceuticals announced that the European Commission has approved ALYFTREK, a once-daily cystic fibrosis treatment combining deutivacaftor, tezacaftor, and vanzacaftor. The approval applies to patients aged six years and older with at least one non-class I CFTR mutation. ALYFTREK is intended to simplify treatment with a once-daily option.

The approval is based on clinical trial results showing that ALYFTREK is not inferior to existing treatments in improving lung function and provides greater reduction in sweat chloride concentration. Vertex plans to make the treatment available across the European Union and has begun access in countries with existing reimbursement agreements.